Hitting a new target with echinocandins. Why chase something else?
Graybill
J R
JR
The University of Texas Health Science Center at San Antonio, Division of Infectious Diseases 78284-7881, USA. JRgraybill@aol.com
D000077612:Anidulafungin; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D054714:Echinocandins; D005656:Fungal Proteins; D006801:Humans; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077612:Anidulafungin; C007572:echinocandin B; D000077336:Caspofungin